BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:lutikizumab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of lutikizumab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06468228-103@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:lutikizumab: Phase 3 readout est. (NCT06468228)
DESCRIPTION:lutikizumab\, phase 3\, Hidradenitis Suppurativa.\nStudy: A Stu
 dy to Assess Disease Activity and Safety of Lutikizumab in Adult and Adole
 scent Participants With Moderate to Severe Hidradenitis Suppurativa\nEstim
 ated primary completion: December 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/lutikizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06468228
URL:https://assetmemo.bio/drug/lutikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06524635-103@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:lutikizumab: Phase 2 readout est. (NCT06524635)
DESCRIPTION:lutikizumab\, phase 2\, Atopic Dermatitis.\nStudy: A Study to A
 ssess Molecular Changes in Adult Participants With Moderate to Severe Hidr
 adenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receivin
 g Subcutaneous Injections of Lutikizumab\nEstimated primary completion: Fe
 bruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lutikizu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06524635
URL:https://assetmemo.bio/drug/lutikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06972446-103@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:lutikizumab: Phase 2 readout est. (NCT06972446)
DESCRIPTION:lutikizumab\, phase 2\, Rheumatoid Arthritis.\nStudy: A Study t
 o Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthr
 itis\nEstimated primary completion: February 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/lutikizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06972446
URL:https://assetmemo.bio/drug/lutikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06718101-103@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:lutikizumab: Phase 2 readout est. (NCT06718101)
DESCRIPTION:lutikizumab\, phase 2\, Atopic Dermatitis.\nStudy: A Study to E
 valuate the Effectiveness and Safety of Treatments\, Either Alone or in Co
 mbination\, for the Treatment of Moderate to Severe Atopic Dermatitis\nEst
 imated primary completion: May 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/lutikizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06718101
URL:https://assetmemo.bio/drug/lutikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06257875-103@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:lutikizumab: Phase 2 readout est. (NCT06257875)
DESCRIPTION:lutikizumab\, phase 2.\nStudy: A Study to Assess Adverse Events
  and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC
 ) Lutikizumab in Adult Participants With Active Ulcerative Colitis\nEstima
 ted primary completion: September 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/lutikizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06257875
URL:https://assetmemo.bio/drug/lutikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05139602-103@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:lutikizumab: Phase 2 readout est. (NCT05139602)
DESCRIPTION:lutikizumab\, phase 2\, Hidradenitis Suppurativa.\nStudy: A Stu
 dy to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-
 981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativ
 a Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Na
 ïve to Biologic Therapy\nEstimated primary completion: December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/lutikizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05139602
URL:https://assetmemo.bio/drug/lutikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06865105-103@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:lutikizumab: Phase 2 readout est. (NCT06865105)
DESCRIPTION:lutikizumab\, phase 2.\nStudy: Study of Targeted Therapies for 
 the Treatment of Adult Participants With Active Psoriatic Arthritis\nEstim
 ated primary completion: August 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/lutikizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06865105
URL:https://assetmemo.bio/drug/lutikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06548542-103@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:lutikizumab: Phase 2 readout est. (NCT06548542)
DESCRIPTION:lutikizumab\, phase 2.\nStudy: Study of Targeted Therapies for 
 the Treatment of Adult Participants With Moderate to Severe Crohn's Diseas
 e\nEstimated primary completion: January 2030. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/lutikizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06548542
URL:https://assetmemo.bio/drug/lutikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
